A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Search:
Medline
CancerConsultants.com
Both
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.350.36 (0.82%)
NVS$54.7-0.04 (-0.07%)
SNY$38.04-0.15 (-0.39%)
GSK$37.82-0.02 (-0.05%)
click here
Latest Clinical News
Multiple-agent Therapy with Metronomic Xeloda® and Nexavar® Promising for Metastatic Renal Cell Carcinoma (3/12/2010)
Researchers from Spain have reported: “Maximum tolerated dose chemotherapy followed by metronomic chemotherapy” is a promising approach for treatment of patients with metastatic renal cell carcinoma (RCC). The details of this study were published early online in Lancet Oncology on February 16, 2010.

Complete Remission Predicts for Long Survival of Patients with Multiple Myeloma (3/12/2010)
Researchers from the M. D. Anderson Cancer Center have reported that achieving a complete remission (CR) was the dominant prognostic factor for long survival of patients with multiple myeloma (MM). The details of this large retrospective review were published in the March 2010 issue of Bone Marrow Transplantation.

More Cancer News
click here
Featured Conference Coverage

ASCO 2009
May 29-June 2, 2009 - Orlando, FL

ASCO 2008
May 30-June 2, 2008 - Chicago, IL

ASH 2008
December 6-9, 2008 - San Francisco, CA

SABCS 2008
December 10-14, 2008 - San Antonio, TX

A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists
March 9-12, 2008 - Tampa, FL

A report from the 2008 ASCO Genitourinary Cancers Symposium
February 14-16, 2008 - San Francisco, CA

 Targeting Angiogenesis in Glioblastoma Multiforme: Highlights and Clinical Implications from ASCO 2008
Physicians: up to 1.0 AMA PRA Category 1 Credit(s)TM.
Pharmacists up to 1.0 contact hour
Nurses up to 1.0 contact hour
Release Date: July 7, 2008
Expiration Date: July 6, 2009
This activity has been supported by an educational grant from Genentech BioOncology

 ASCO 2008: Updates in Bone Health Supportive Care Strategies
Physicians: up to .50 AMA PRA Category 1 Credit(s)TM.
Release Date: June 30, 2008
Expiration Date: June 30, 2009
This activity has been supported by an educational grant from Novartis Oncology.

 Update in the Management of Gastrointestinal Stromal Tumors (GIST): A Report from ASCO 2008
Physicians: up to .50 AMA PRA Category 1 Credit(s)TM.
Release Date: June 30, 2008
Expiration Date: June 30, 2009
This activity has been supported by an educational grant from Novartis Oncology.

 Targeted Therapy and Genitourinary Malignancies: What You Need to Know from ASCO 2008
Physicians: up to .50 AMA PRA Category 1 Credit(s)TM.
Release Date: June 30, 2008
Expiration Date: June 30, 2009
This activity has been supported by an educational grant from Novartis Oncology.

A Report from the 2008 Meeting of the American Society of Clinical Oncology

Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia
Dean Buckner, MD, Fred Hutchinson Cancer Research Center

Highlights of Treatment of Hematological Malignancies
Hagop Kantarjian, MD, The University of Texas, MD Anderson Cancer Center

Breast Cancer Update
Lee Schwartzberg, MD, FACP, Director of the West Clinic, Memphis, TN

The Evolving Role of EGFR Inhibitors in Colorectal Cancer
Jennifer Maxon


A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists

Updates in the Management of Gynecologic Cancers

A report from the 2008 ASCO Genitourinary Cancers Symposium

Updates in the Management of Prostate and Kidney Cancers - CME
Latest Legislative News
Latest FDA News
Arzerra™ Granted Accelerated Approved for Refractory Chronic Lymphocytic Leukemia (10/28/2009)
Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab).

Second HPV Vaccine Approved in U.S. (10/16/2009)
The U.S. Food and Drug Administration has approved Cervarix®, a vaccine against two high-risk types of human papillomavirus (HPV), for prevention of cervical cancer and cervical precancers. This is the second HPV vaccine to be approved in the United States.

More FDA News News »
More FDA News

We Need Your Feedback
Click Here to Participate in Our Feedback Survey

Disease Centers

Additional Conference Coverage, CME, and News by Disease Type
Supportive Care Centers
Physician Resources
Scientific Advisors
© 1998-2010 CancerConsultants.com  All Rights Reserved.